SLE is a chronic autoimmune disease involving multiple systems. Patients with SLE are highly susceptible to infections due to the combined effects of their immunosuppressive therapy and the abnormalities of the immune system that the disease itself causes, which can increase mortality in these patients. The differentiation of SLE activity and infection in a febrile patient with SLE is extremely difficult. Activity indexes are useful to identify patients with lupus flares but some clinical and biological abnormalities may, however, make it difficult to differentiate flares from infection. Several biological markers are now recognized as potential tools to establish the difference between SLE activity and infection, including CRP and procalcitonin. It is possible, however, that the use of only one biomarker is not sufficient to confirm or discard infection. This means that new scores, which include different biomarkers, might represent a better solution for differentiating these two clinical pictures. This review article describes several markers that are currently used, or have the potential, to differentiate infection from SLE flares.
Introduction
Infections are the main cause of early death in patients with SLE [1] . It has been estimated that $25% of SLE patients die due to infections [25] .
There are several risk factors for the development of infections [58] including the use of immunosuppressive drugs (i.e. steroids, CYC and newer treatments including biologics such as belimumab), high disease activity and LN. Most infectious complications in SLE are bacterial [8] , including respiratory, urinary and soft tissue infections [1] .
Assessment of these patients is an important diagnostic challenge, since the initial clinical presentation of a patient with lupus is very similar to the acute febrile phase of an infection (such as sepsis). It is necessary to distinguish between these two possibilities, given the serious clinical consequences of mistakenly treating an infection with immunosuppression or a flare with antibiotics. A predictor marker therefore needs to have high specificity and sensitivity for determining whether the patient is presenting an infection or an SLE flare [9] . This review of the current literature shows the markers used during infections/sepsis, their behaviour in SLE patients and their utility for the differential diagnosis of these two clinical conditions in SLE, and proposes new biomarkers that can be evaluated in this clinical context.
How should SLE activity be determined?
Without a specific biomarker, researchers have tried to objectify clinical findings with indexes in order to grade SLE disease activity. The most commonly used biomarkers are anti-dsDNA antibodies, complement (C3 and C4), ESR, anti-C1q antibodies and activity on urinary sediment, which have been added to certain scales. These scales include the SLEDAI, the BILAG-2004 index, the SLAM, the Systemic Lupus Activity Index (SLAI), the ECLAM and the Systemic Lupus Activity Questionnaire for Population Studies [9] .
Among them, the ECLAM, SLAM, SLEDAI, LAI and Systemic Lupus Activity Questionnaire provide a single summary score for activity, while the BILAG provides assessment scales for individual organs and systems. Summary scores are sometimes limited, as the same score may be associated with different types of disease severity (multiple mild manifestations compared with a single severe manifestation). Furthermore, improvement in one organ may be accompanied by worsening in another organ, while the summary score may remain unchanged. Taking these problems in that order, the BILAG-2004 index seems to better detect disease activity requiring increased treatment.
How should lupus flare and infection be differentiated?
Predictor markers of infection have been extensively studied in different populations, especially in intensive care unit patients. An ideal marker for infection should be highly sensitive and specific, easy to use, fast, and inexpensive, and should also correlate with the severity and prognosis of infection [10] .
Biomarkers in SLE
The most commonly used markers in SLE include antidsDNA antibodies, complement, ESR, anti-C1q antibodies [11] , urinary sediment and SLEDAI score. Their efficacy and value in the prediction of exacerbations has been extensively evaluated [12, 13] . These markers are, however, not specific and also lack the precision to differentiate between infections and flares. Their levels can, in fact, decrease due to the use of immunosuppressive therapies [14] . New biomarkers that are being used to evaluate disease activity include serum cytokines, soluble cytokine receptors, soluble and/or surface molecules (CD27, CD154), growth factors (B cell activating factor), markers of endothelial activation, cell markers (CD27 high in plasma cells) and activation of complement (erythrocyte C4d) among others [15] . Due to the proinflammatory condition of SLE patients, the interpretation of these markers may, however, have pathophysiological differences.
Possible biomarkers of infection in SLE patients
There are few studies that evaluate the diagnostic role of different markers to detect infection in patients with autoimmune diseases, even fewer in patients with SLE. The most widely studied markers in the context of SLE and autoimmune diseases are the discussed below.
CRP
Known as an inflammatory biomarker, CRP is an acute phase reactant synthesized by the liver during IL-6 regulation. In inflammation, it binds to the membrane phospholipids of microorganisms or damaged cells to facilitate the removal of these by macrophages, decreasing the likelihood of immune responses to nuclear antigens. CRP has also the ability to opsonize bacteria, activate the complement pathway, and bind FcR on phagocytes, facilitating elimination of pathogens [16, 17] . It is also common, however, to find high levels of CRP in rheumatic diseases such as RA, vasculitis and SLE; this decreases its specificity, making it even more difficult to differentiate between infection or disease reactivation [18] . CRP increases significantly in SLE patients with concomitant infection, but increases only slightly or not at all in patients with a lupus flare and no infection, unlike in other autoimmune diseases such as RA [19] . The explanation of this phenomenon is not clear but the presence of CRP autoantibodies [2022] , genetic differences in the ability to respond to certain stimuli [23] , and reduced production or defects in the action of IL-6 [24, 25] have been proposed. Furthermore, high-sensitivity CRP (hsCRP) with values above 6 mg/dl may be associated with active infection with an 84% specificity in SLE patients [19] . It has been found that the ESR/CRP ratio may be useful to differentiate between infection and flare in SLE patients, where a ratio above 15 was significantly correlated with disease activity and a ratio below 2 was associated with infection [19] . However, other studies have shown less utility of CRP in SLE patients. For this reason, the study of new markers is mandatory.
Procalcitonin
Procalcitonin (PCT) is a precursor peptide of calcitonin associated with invasive bacterial infections. Normally produced by parafollicular C cells, it is released in response to bacterial toxins and IL-1b stimulus. PCT levels increase within the first 24 h of infection onset, reach a peak between 24 and 48 h and immediately decrease at the end of a bacterial infection [18, 26] . The mechanism proposed for PCT production after inflammation and its role are still not completely known.
PCT is virtually undetectable in healthy people. It has also been found to be elevated in certain autoimmune diseases such as systemic vasculitis [26] , granulomatosis with polyangiitis [27] , Kawasaki disease [28] and adult-onset Still's disease [29] , without evident infection. In these diseases, however, high PCT levels have not been associated with disease activity [18, 30] . Nevertheless, the information regarding plasma PCT levels in patients with active underlying systemic autoimmune diseases is limited, primarily from observational studies and case series, with considerable variability of patient characteristics and clinical settings. The exact role of high PCT in these autoimmune conditions is not understood. Additionally, there is no evidence of any effect on PCT levels of glucocorticoids or NSAIDs [18, 26] .
PCT has a higher diagnostic value than CRP in the detection of bacterial sepsis in patients with autoimmune diseases, with a sensitivity of 75% and a specificity of 90% [31] . It was therefore considered more sensitive and specific than CRP in the detection of bacterial infections in 44 patients with autoimmune diseases, including 10 SLE patients [29] . In SLE patients, it has been found that a value >0.38 ng/ml has a 74.5% sensitivity and a 95.5% specificity, a high positive predictive value of 92.1% and a negative predictive value of 84.2% for the differentiation of infection and disease activity [18] . PCT measurement is therefore useful in monitoring patient response to antibiotic treatment [18] . Performance of this test to differentiate SLE flare and bacterial infection varied, however, according to the cutoffs selected [18] . A meta-analysis has shown that PCT levels 50.5 mg/ml can differentiate between the two conditions, but a value of 0.38 mg/l is more appropriate because 10 and 50% of patients with SLE who have renal activity have slightly elevated PCT levels [30] . It should, however, be noted that PCT levels also rise in non-septic inflammatory conditions such as Post-surgery, post-resuscitation, cardiogenic shock, severe pancreatitis or rhabdomyolysis [32] .
Mannose binding lectin
Mannose binding lectin (MBL) is an innate immune system protein that recognizes membrane carbohydrate residues of different microorganisms and activates the complement system via associated proteases [33] . MBL is produced by the liver and the associated protease is MBL-associated serine protease. MBL is a member of the class of collectins in the C-type lectin superfamily. It also binds necrotic and dying cells, avoiding autoimmune reactivity [33] . MBL's levels and function vary according to MBL2 gene polymorphism. A serum level over 0.5 mg/ml (82% sensitivity, 82% specificity and 98% negative predictive value) is associated with increasing risk of death in infected patients without SLE infected by pneumococcus [34] . MBL polymorphisms have, in multiple populations, been associated with SLE development, although the physiopathological mechanisms are not fully understood [35] .
MBL deficiency provokes the inefficient removal of apoptotic cells, stimulating antibody formation, which may be implicated in SLE pathogenesis [3537] . There is evidence, however, that serum MBL levels relate to SLE activity compared with other markers such as antidsDNA, C3/C4 levels and SLEDAI score [38, 39] . Compared with healthy controls, MBL levels are higher in patients with SLE and can be grouped into categories according to the organ involved. Low levels of MBL are seen in patients with musculoskeletal and cutaneous manifestations while intermediate or high levels are seen in patients with nephritis [38] . Nevertheless, the distinction between infection and disease activity levels has not been evaluated.
CD64
CD64 or Fc-gamma receptor 1 (FcgR1) is a high-affinity receptor expressed on monocytes, macrophages and weakly on neutrophils. It binds to IgG, primarily IgG1 and IgG3 subtypes. Basal expression of CD64 on circulating neutrophils (nCD64) is low, increasing considerably in response to exposure to bacterial components, complement fractions and some inflammatory cytokines (IFN-g or G-CSF) during the first 46 h of exposure to stimulating molecules [40, 41] . These features indicate its utility as a possible marker for sepsis at early stages [4244] and in different age groups [42, 45] . An nCD64 index >2.2 (by flow cytometry) is a good predictor of bacterial infection with a sensitivity and specificity of 63% (5571%) and 89% (8394%), respectively, in all kind of patients admitted to the intensive care unit [46] . New research has validated its usefulness in the early diagnosis of sepsis in combination with CRP and other biomarkers, and it may be useful even in clinical follow-up [47, 48] .
Concerning SLE patients, increased CD64 expression has been found in circulating monocytes related to inflammatory response and kidney involvement, but these levels are not elevated on neutrophils, indicating that nCD64 expression may be related to an infectious disease in SLE. It is suggested that immune complexes and proinflammatory mediators increase the expression of CD64 in SLE monocytes [49] . Similarly, CD64 has been proposed as a surrogate marker of IFN signature involved in SLE pathogenesis [50] .
There are only a few studies, with significant limitations, evaluating the usefulness of CD64 to differentiate between infection and SLE flare. In a study including 19 patients with SLE and 24 with RA, the nCD64 expression was significantly higher in patients with active autoimmune disease and infection compared with healthy controls and/or patients with inactive disease. It was suggested that nCD64 level 543.5% has a 94.4% sensitivity and 88.9% specificity to detect an infection in patients with SLE and RA [41] , making this marker one of the most promising for the differentiation of bacterial infection and SLE flare. Larger studies with a higher number of SLE patients must be performed in order to validate CD64 as a useful test.
High mobility group box chromosomal protein 1
The high mobility group box chromosomal protein 1 (HMGB1) is a member of a group of nuclear non-histone proteins [51] that bind to dsDNA, ssDNA and nucleosomes, participating in transcriptional regulation [52] . This protein is also one of the damage associated molecular pattern proteins, due to the release of HMGB1 from dying cells during the processes of necrosis, apoptosis or NETosis (a type of cell death associated with the production of neutrophil extracellular traps involved in the pathogenesis of autoimmunity), and as a late response cytokine [53, 54] . Extracellular HMGB1 is involved in inflammatory processes and has the ability to stimulate monocytes/ macrophages to produce pro-inflammatory cytokines [55] . The biological actions occur through binding to the cell surface receptor of advanced glycation end products [56] , and toll like receptor (TLR) 2, TLR4 and TLR9 [57] . In sepsis, HMGB1 levels are increased. Several reports show that extracellular HMGB1 acts as a late mediator of sepsis, worsening the prognosis and survival. Currently some inhibitors of HMGB1 are being evaluated as a target treatment for sepsis [5860] . Clinical reports show that HMGB1 levels are increased in sepsis [61] , severe sepsis and septic shock [62] .
Recently these proteins have been implicated in the pathophysiology of autoimmunity. In SLE patients, two routes for HMGB1-led pathogenesis have been described: one through the formation of complexes with nucleosomes that induce an inflammatory immune response, and the other through alteration of the phagocytosis and/or binding of HMGB1 to surface phosphatidylserine of apoptotic neutrophils. HMGB1 is also known to induce NETosis through interaction with TLR4 [51, 63] . The binding of HMGB1 to Gadd45a, a protein involved in the processes of DNA demethylation in CD4 + T lymphocytes, is another recently described mechanism [64] . In general, HMGB1 has been proposed as a new biomarker for SLE because its concentrations are higher in SLE and SLE flares compared with healthy controls [64, 65] . During disease activity, levels of HMGB1 (most important) and HMGB1 antibodies are notably increased in patients with renal involvement, correlated with SLEDAI, dsDNA levels and proteinuria [66, 67] . Currently, there are no studies comparing the sensitivity and specificity of this biomarker to differentiate infection and/or sepsis vs disease activity in SLE patients. , an enzyme involved in the degradation of RNA and protection from viral infections, is induced by type I IFN; when activated by dsRNA, OAS binds to RNAase-L. OAS has been described on peripheral lymphocytes in SLE [68] . There are different isoforms of OAS: OAS1, OAS2, OAS3 and OAS-like (OASL) protein [69, 70] . OAS's main function is the control of virus replication, but some genetic polymorphisms alter its capacity for RNA degradation, raising the risk of infections [71, 72] . In one study evaluating the IFN induction in SLE patients, OAS1 and OASL corresponded to 21% of IFN-induced genes. Other genes induced by IFN were LY6E, MX1 and ISG15 [73] .
In SLE, the expression of OAS1, OAS2 and OAS3 was increased 8.14, 6.21 and 6.96%, respectively, compared with patients with other rheumatic diseases [74] . In patients with active SLE, transcription of OAS1, OAS2 and OASL mRNAs is increased compared with infected patients or healthy individuals. For those patients with SLE and infection, OAS1 is increased and OASL is decreased. High levels of OASL are negatively correlated with the presence of infection in complicated SLE, suggesting that OAS1 and OASL may be a differentiator of infection and lupus activity [75] . OASL expression also correlates with ESR values in SLE patients unlike expression of other kinds of genes induced by type I IFN [71] .
Soluble triggering receptor expressed on myeloid cells type 1
The triggering receptor expressed on myeloid cells type 1 (TREM-1) has been identified on the surface of mature neutrophils and monocytes responding to bacterial and fungal infections. Its production is regulated by lipoteichoic acid and bacterial lipopolysaccharide, activating the signalling associated with activation protein of 12 kDa (DAP12) [76, 77] . Activation of TREM-1 in the presence of TLR-2 or TLR-4 ligands amplifies the production of proinflammatory cytokines, which is associated with a worse outcome in murine sepsis models. Increasing membrane expression of TREM-1 is associated with the release of the soluble form (sTREM-1) in sepsis [78] .
The release of sTREM-1 in SLE, makes this a new activation pathway in SLE [79] . It has been found that sTREM-1 levels are elevated in SLE patients with infection when compared with healthy subjects (1.1 vs 0.11 pg/ml) [79] . In this same study, SLE patients with signs of lupus flare without infection showed a higher value of sTREM-1 compared with both healthy subjects and SLE patients without signs of activity (2.9 vs 0.8 pg/ml, respectively) [79] . In other studies, sTREM-1 was found to be useful for differentiating infection and disease activity (109.9 vs 48.0 pg/ml, respectively), with a sensitivity and specificity of 100 and 66%, respectively, for values >53.2 pg/ml [80] . sTREM-1 levels are correlated with ESR but not with other markers [79] .
CD27

++
The CD27 protein belongs to the family of TNF receptors expressed on T and B lymphocytes. Its ligand, the CD70 antigen, is present on NK cells and subsets of B and T cells. CD27 on B cells is quickly activated upon B cell stimulation and it is associated to high immunoglobulin secretion [81] . In healthy controls, CD27 is expressed in high quantity only in 12% of cells [82] . The percentage of CD27 high expression on B cells of SLE patients is, however, higher than in healthy subjects (15.5 vs 2.3%, respectively) [83] . In addition, the percentage of CD27 high is significantly increased in patients with infection but without SLE (57.2%) compared with SLE infected patients (43.1%) [83] . In SLE flare, 86% of the patients had a high expression of CD27
++ on their plasma cells compared with SLE nonactive patients [84] , and this was correlated with antidsDNA antibodies, SLEDAI score and C3/C4 levels [83, 84] . CD27 could therefore be a good marker of disease activity.
Delta neutrophil index
The delta neutrophil index (DNI) is a new index determined by subtracting the fraction of mature polymorphonuclear leucocytes from myeloperoxidase reactive cells [85, 86] . Quantification of immature granulocytes can therefore be used as a marker of bacteraemia or sepsis [8789] . DNI has been proven to have an association with disseminated intravascular coagulation [85] , bacteraemia [85] , positive cultures [85] and 28-day mortality in sepsis [86] . When compared with other infection markers, a high DNI is better than CRP in correlating with severe sepsis or septic shock in critically ill patients [86, 90] , meaning that DNI might be useful as a marker for the early diagnosis and prognostics of septic patients [86] .
There is only one study in SLE patients. It evaluated the utility of DNI to differentiate infection from disease activity (SLEDAI >3) in patients who presented with fever and infection (positive cultures or radiological findings) [9193] . A DNI cutoff of 2.8% (54.3% sensitivity and 87.7% specificity) suggested an increased risk of infection (risk ratio 8.48; P < 0.001) [93] . These findings showed that DNI measurement can be useful to differentiate infection from lupus flare in febrile SLE patients.
Scores in sepsis
Despite these new markers, none used alone has enough power to confirm or exclude an infection. For this reason, the combination of two or more tests has been proposed to more accurately predict the diagnosis and monitoring of sepsis in critically ill patients. The use of nCD64 and CRP has, for example, been proposed to determine whether combining these two biomarkers would have higher diagnostic value than their sole use. When both markers were abnormal, the probability of sepsis was 92% and when the two markers were normal, the diagnosis of sepsis was excluded with a probability of 99% (76% sensitivity and 98% specificity) [47] .
Furthermore, it was found that the mean fluorescence intensity of nCD64 was able to predict the response to antibiotics [47] . A value >260 mean fluorescence intensity on the fourth day of antibiotic treatment was significantly associated with treatment failure (93% sensitivity and 48% specificity) [47] . A biological score (BioScore) that measured sTREM-1, PCT and nCD64 has been developed [48] . nCD64 showed the best diagnostic profile (95.2% specificity and 84.4% sensitivity) [48] . The BioScore increases the probability of sepsis, showing an infection rate of 3.8% for a BioScore of 0 (all negative tests) to 100% for a BioScore of 3 [48] . Currently, there are no data for SLE patients using a BioScore. The analysis of combined biomarkers in SLE must be performed carefully due to the possible confounder factors in lupus flares.
Discussion and conclusion
Despite advances in critical care medicine and the development and availability of broad-spectrum antibiotics, infections continue to be a major cause of mortality in critically ill patients. This has encouraged research on biomarkers that allow early diagnosis and aggressive treatment in patients with suspected infection [94] .
SLE patients represent a very complicated population, because their pathophysiological disease factors are not well defined and may be diverse in different patients, all resulting in a proinflammatory state. In addition, treatments used to suppress this inflammatory state may cause immunosuppression, predisposing them to developing infections [95] . It is challenging to differentiate between a diagnosis of flare and infection in a febrile SLE patient because the two conditions share many of the same results in clinical and laboratory tests [19] . Table 1 summarizes the main markers that may be used to evaluate this clinical scenario. PCT and CRP have been the two most studied biomarkers, with successful results in some series. New biomarkers including CD64, OAS and sTREM-1 have been evaluated in smaller cohorts of SLE patients. It is possible, however, that an isolated biomarker will not be sufficient to confirm a diagnosis of sepsis. The development of a BioScore may increase the diagnostic power of biomarkers and provide a faster way to the correct treatment [48] . It is clear that more research is needed in order to differentiate infection from lupus flare.
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